SIRP{alpha}-CD47 Blockade-Mediated Tumor Cell Phagocytosis Requires SLAMF7 [Immunotherapy]
SLAMF7 expression is required for macrophage-mediated phagocytosis of hematopoietic tumor cells. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Immunotherapy Source Type: research
Chromosome Instability Drives Tumor Evolution [News in Depth]
A prospective study of patients with non–small cell lung cancer undergoing treatment reveals that chromosomal instability and tumor heterogeneity drive disease recurrence. Researchers involved in the TRACERx trial documented that genetic diversity by sequencing multiple regions of the primary tumor and then created bespoke ctDNA tests that allowed for early detection of relapse and metastasis. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Depth Source Type: research
Noted [News in Brief]
A collection of recently published news items. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Four Groups Win CRUK "Grand Challenge" [News in Brief]
Four research teams were each awarded Cancer Research UK's "Grand Challenge" prize of up to £20 million, or about $25 million, over 5 years. The winning teams bring together scientists and technologists from around the world to tackle some of the most pressing unsolved problems in cancer research. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Exploiting Defective DNA Repair in IDH-Mutant Cancers [News in Brief]
Data from a preclinical study suggest rethinking the "oncometabolite hypothesis," which calls for blocking the product of neomorphic IDH1/2 mutations to halt tumor progression. Instead, exploiting the vulnerability of IDH1/2-mutant tumor cells to PARP inhibition, as a result of defective DNA repair, appears to be a more effective strategy that will soon be tested in the clinic. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Medical Centers Sign On to Single IRB Model [News in Brief]
All 64 member institutions of the NIH's Clinical and Translational Science Awards program have agreed to a common framework for running multisite trials under the umbrella of just one Institutional Review Board. The NCI has long offered a centralized review board option. Come September, single Institutional Review Boards will be mandatory for all NIH-backed studies. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Indoximod Combo Triggers Responses in Melanoma [News in Brief]
Adding the investigational IDO-pathway inhibitor indoximod to checkpoint inhibitor therapy resulted in a 52% overall response rate in patients with advanced melanoma enrolled in a phase II trial. The combination strategy has potential as an alternative for patients whose tumors do not respond to standard therapy. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Biden: Progress Made with Cancer Moonshot [News in Brief]
In an address to attendees at the American Association for Cancer Research Annual Meeting 2017, former Vice President Joe Biden urged optimism in the fight against cancer despite threats of funding cuts under the Trump administration. He also spoke about progress that has been made as part of the Beau Biden Cancer Moonshot. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
People [News in Brief]
Bruce E. Johnson, MD; Carl H. June, MD; and Brian J. Druker, MD, are highlighted. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
In This Issue [In This Issue]
(Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: In This Issue Source Type: research
LACTB May Be a Tumor Suppressor Gene in Breast Cancer [Tumor Suppressors]
LACTB promotes breast cancer cell differentiation and suppresses breast tumorigenesis in vivo. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Tumor Suppressors Source Type: research
LGR5+ Cancer Stem Cells Drive Primary and Metastatic Colorectal Cancer [Stem Cells]
LGR5+ colorectal cancer CSCs are dispensable for primary tumor growth due to plasticity. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Stem Cells Source Type: research
A FOXO4 Inhibitory Peptide Limits Chemotoxicity in Mice [Senescence]
The FOXO4 inhibitory peptide FOXO4-DRI promotes targeted apoptosis of senescent cells. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Senescence Source Type: research
ROCK Inhibition Primes Tumor Tissue to Sensitize Cells to Chemotherapy [Pancreatic Cancer]
Short-term ROCK targeting improves cytotoxic drug efficacy in primary and metastatic pancreatic cancers. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Pancreatic Cancer Source Type: research
Ascorbate Alters Iron Metabolism to Drive Anticancer Toxicity [Metabolism]
Ascorbate disrupts iron metabolism to cause H2O2-mediated oxidative damage to NSCLC and GBM. (Source: Cancer Discovery)
Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: Metabolism Source Type: research
